XML 39 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Revenue, Segment Profit and Segment Expenses The following table illustrates reported segment revenue, segment profit and significant segment expenses (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

NUPLAZID net revenue

 

$

159,721

 

 

$

129,923

 

DAYBUE net revenue

 

 

84,596

 

 

 

75,908

 

Total revenues

 

 

244,317

 

 

 

205,831

 

Less:

 

 

 

 

 

 

Cost of goods sold

 

 

9,211

 

 

 

10,074

 

License fees and royalties

 

 

11,181

 

 

 

12,877

 

Research and development expense:

 

 

 

 

 

 

External research and development

 

 

54,985

 

 

 

41,489

 

Internal costs(1)

 

 

23,280

 

 

 

18,190

 

Total research and development expense

 

 

78,265

 

 

 

59,679

 

Selling, general and administrative

 

 

126,370

 

 

 

107,991

 

Interest income, net

 

 

(7,901

)

 

 

(5,506

)

Other income

 

 

(588

)

 

 

(286

)

Income tax expense

 

 

8,792

 

 

 

4,447

 

Consolidated net income

 

$

18,987

 

 

$

16,555

 

_______________

(1)
Includes personnel expenses and costs allocated to multiple research and development programs, including benefits, information technology, facilities and inventory.